{"id":53658,"date":"2023-02-06T19:02:04","date_gmt":"2023-02-06T18:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/"},"modified":"2023-02-06T19:02:04","modified_gmt":"2023-02-06T18:02:04","slug":"slingshot-biosciences-announces-11-million-in-series-a3-financing","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/","title":{"rendered":"Slingshot Biosciences Announces $11 Million in Series A3 Financing"},"content":{"rendered":"
\n

\nDeveloping synthetic cells for a range of applications in diagnostics and therapeutics<\/i>\n<\/p>\n

<\/a><\/p>\n

EMERYVILLE, Calif.–(BUSINESS WIRE)–Slingshot Biosciences<\/a>, a biotechnology company building the world\u2019s first on-demand synthetic cell platform for customizing cell and cell line mimics, today announced the closing of $11 million in a Series A3 financing.\n<\/p>\n

\nThe investment was co-led by ARCH Venture Partners<\/a> and Northpond Ventures<\/a>, with participation from Anterra Capital<\/a>. The new funding will enable Slingshot to accelerate the successful commercialization of its revolutionary technology for cell and gene therapies. Slingshot will also further its adoptive cell therapy and therapeutics platform with this financing.\n<\/p>\n

\n\u201cSlingshot\u2019s synthetic cell platform will have a transformative impact on a wide range of critical healthcare markets, including cell and gene therapy,\u201d said Corey Ritter of ARCH Venture Partners. \u201cAll of us at ARCH are excited to work with the Slingshot team to make these synthetic cell products widely accessible to address research, diagnostics, and manufacturing needs, while advancing their functional synthetic cell efforts.\u201d\n<\/p>\n

\n\u201cAfter successfully building our commercial footprint in controls and diagnostics last year, we are thrilled to accelerate our strategic efforts for biopharma applications, specifically cell and gene therapies,\u201d said Jeffrey Kim, PhD, Founder, CEO, and President of Slingshot. \u201cCustomer traction is phenomenal, and we are excited to double down on our commercialization and development efforts for cell and gene therapy customers.\u201d\n<\/p>\n

\nCell-derived products are essential to healthcare technologies worldwide. Seven hundred and fifty (750) blood samples are tested every second in the U.S. alone, and each of these tests relies on cell-derived references for accurate measurement.\n<\/p>\n

\nWith this additional financing, Slingshot is developing the next generation of adoptive cell therapy tools and therapeutic modalities that can benefit from its synthetic cell platform. Slingshot will also further invest in its functional cell programs for biopharma applications.\n<\/p>\n

\nAbout Slingshot Biosciences<\/span><\/b>\n<\/p>\n

\nSlingshot Biosciences develops synthetic cells for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf solution for cell-like reagents that are stable, low-cost, and targeted toward a range of indications and markets. www.slingshotbio.com<\/a>.\n<\/p>\n

\nAbout ARCH Venture Partners<\/span><\/b>\n<\/p>\n

\nARCH Venture Partners invests in advanced technology companies and is one of the world\u2019s leading early-stage technology venture firms. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories. ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market. www.archventure.com<\/a>.\n<\/p>\n

\nAbout Northpond Ventures<\/span><\/b>\n<\/p>\n

\nNorthpond Ventures is a multi-billion-dollar science-driven venture capital firm based in Cambridge, MA; San Francisco, CA; and Bethesda, MD. Northpond has consistently been named one of the most active lead life science investors by both Crunchbase and Silicon Valley Bank. It is deeply engaged in the academic ecosystem, having founded The Laboratory for Bioengineering Research and Innovation at Harvard\u2019s Wyss Institute; launched the MIT-Northpond Program – Advancing Life Science & Engineering Innovation; and sponsored a prize for women entrepreneurs at MIT. It has led or co-led over 60 financings over the past several years and sits on the board of the vast majority of these businesses. www.npv.vc<\/a>.\n<\/p>\n

\nAbout Anterra Capital<\/span><\/b>\n<\/p>\n

\nWith offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with transformative potential in food, agriculture, and animal health. Supported by multinational institutional investors, Anterra provides patient strategic capital to entrepreneurs and innovative companies sustainably transforming our global food system. www.anterracapital.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCaitlin Farquhar
\n
pr@slingshotbio.com<\/a>\n<\/p>\n

\nAurora Silva
\n
media@crosswindpr.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Developing synthetic cells for a range of applications in diagnostics and therapeutics EMERYVILLE, Calif.–(BUSINESS WIRE)–Slingshot Biosciences, a biotechnology company building the world\u2019s first on-demand synthetic cell platform for customizing cell and cell line mimics, today announced the closing of $11 million in a Series A3 financing. The investment was co-led by ARCH Venture Partners and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53658","6":"format-standard","7":"category-industry"},"yoast_head":"\nSlingshot Biosciences Announces $11 Million in Series A3 Financing - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Slingshot Biosciences Announces $11 Million in Series A3 Financing - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Developing synthetic cells for a range of applications in diagnostics and therapeutics EMERYVILLE, Calif.–(BUSINESS WIRE)–Slingshot Biosciences, a biotechnology company building the world\u2019s first on-demand synthetic cell platform for customizing cell and cell line mimics, today announced the closing of $11 million in a Series A3 financing. The investment was co-led by ARCH Venture Partners and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-06T18:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230206005236\/en\/1705513\/21\/primary_full.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Slingshot Biosciences Announces $11 Million in Series A3 Financing\",\"datePublished\":\"2023-02-06T18:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/\"},\"wordCount\":609,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230206005236\\\/en\\\/1705513\\\/21\\\/primary_full.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/\",\"name\":\"Slingshot Biosciences Announces $11 Million in Series A3 Financing - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230206005236\\\/en\\\/1705513\\\/21\\\/primary_full.jpg\",\"datePublished\":\"2023-02-06T18:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230206005236\\\/en\\\/1705513\\\/21\\\/primary_full.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230206005236\\\/en\\\/1705513\\\/21\\\/primary_full.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/slingshot-biosciences-announces-11-million-in-series-a3-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Slingshot Biosciences Announces $11 Million in Series A3 Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Slingshot Biosciences Announces $11 Million in Series A3 Financing - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/","og_locale":"en_US","og_type":"article","og_title":"Slingshot Biosciences Announces $11 Million in Series A3 Financing - Pharma Trend","og_description":"Developing synthetic cells for a range of applications in diagnostics and therapeutics EMERYVILLE, Calif.–(BUSINESS WIRE)–Slingshot Biosciences, a biotechnology company building the world\u2019s first on-demand synthetic cell platform for customizing cell and cell line mimics, today announced the closing of $11 million in a Series A3 financing. The investment was co-led by ARCH Venture Partners and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-06T18:02:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230206005236\/en\/1705513\/21\/primary_full.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Slingshot Biosciences Announces $11 Million in Series A3 Financing","datePublished":"2023-02-06T18:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/"},"wordCount":609,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230206005236\/en\/1705513\/21\/primary_full.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/","url":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/","name":"Slingshot Biosciences Announces $11 Million in Series A3 Financing - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230206005236\/en\/1705513\/21\/primary_full.jpg","datePublished":"2023-02-06T18:02:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230206005236\/en\/1705513\/21\/primary_full.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230206005236\/en\/1705513\/21\/primary_full.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/slingshot-biosciences-announces-11-million-in-series-a3-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Slingshot Biosciences Announces $11 Million in Series A3 Financing"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53658"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53658\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}